Dyspnea Clinical Trial - Effects of P2Y12 Receptor Inhibitors on Central &

Status Recruiting

Clinical Trial Summary

Research project objectives: Most common complication of P2Y12 inhibitors treatment, particularly with ticagrelor, is dyspnea reported in 0 to 9.3% and in 10 to 38.6% of patients taking clopidogrel and ticagrelor respectively. Pathogenesis of the P2Y12 inhibitors-induced dyspnea is unknown; however, recently published case reports suggests activation of chemosensory areas. The primary objective of this study is to assess the influence of most commonly used in clinical practice P2Y12 inhibitors - ticagrelor and clopidogrel - on central and peripheral chemosensitivities. The secondary objective of the study is to define the relationship between baseline chemosensitivity (assessed before the drug initiation) and the occurrence of dyspnea after the drug administration. Methodology: Patients undergoing percutaneous coronary angioplasty (PCI), who according to current European Cardiac Society Guidelines are prescribed with various P2Y12 inhibitors (drug choice depends on individual clinical situation), will be enrolled to the study. Patients will be assigned to 2 groups depending on the type of P2Y12 inhibitor prescribed: Group A -patients receiving ticagrelor, Group B -patients receiving clopidogrel. In both groups chemosensitivity assessment will be performed before P2Y12 inhibitor administration and after the drug initiation. Patients will be additionally asked to fill the questionnaire regarding dyspnea sensation during the treatment (VAS scale and investigator-designed questionnaire). Peripheral chemosensitivity assessment will be performed using transient hypoxia method, when progressive hypercapnic test will be employed to test central chemosensitivity. Blinded recordings of chemosensitivity tests will be analyzed by researcher not involved in data collection. Chemosensitivities prior to and after drugs initiation will be compared separately for groups A and B using appropriate statistical tests. The results of dyspnea sensation questionnaire will be compared between patients with high- and low- peripheral chemosensitivity (assessed before P2Y12 inhibitor initiation) within particular groups.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Dyspnea

Clinical Trial Details

NCT number	NCT05080478
Study type	Observational
Source	Wroclaw Medical University
Contact	Stanislaw Tubek, MD, PhD
Phone	00 48 71 733 11 12
Email	stanislaw.tubek@umw.edu.pl
Status	Recruiting
Phase
Start date	November 1, 2018
Completion date	August 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04688905` - Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)
Completed	`NCT03679312` - The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD	Phase 1/Phase 2
Recruiting	`NCT04868357` - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program	N/A
Active, not recruiting	`NCT03604822` - Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS	N/A
Completed	`NCT03626519` - Effects of Menthol on Dyspnoea in COPD Patients	N/A
Completed	`NCT02638649` - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Completed	`NCT02248831` - Evaluation of Cardiopulmonary Diseases by Ultrasound	N/A
Completed	`NCT02538770` - Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization	N/A
Terminated	`NCT02269761` - Chest Ultrasound of ER Patients With Cough or SOB
Recruiting	`NCT01655199` - Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease	N/A
Active, not recruiting	`NCT01440764` - Aerosol Inhalation Treatment for Dyspnea	Phase 1/Phase 2
Completed	`NCT01577407` - Non Opioid Treatment for Experimental Dyspnea	Phase 3
Completed	`NCT01193998` - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department	N/A
Recruiting	`NCT04327882` - Point-of-care Ultrasound Interest in Dyspneic Emergency Department Patients: an Observational Bicentric Study
Completed	`NCT05029986` - Preventing Dyspnea During Speech in Older Speakers	N/A
Not yet recruiting	`NCT04181359` - The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.	Phase 1/Phase 2
Recruiting	`NCT04615065` - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed	`NCT04305639` - The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)"
Completed	`NCT04375917` - Is Reduced Hypoxia Through a Robot Intervention, Associated With Sensory and Emotional Descriptions of Dyspnea, Anxiety, Depression, Symptom Burden and Anxiolytics	N/A
Completed	`NCT04370990` - Automated Oxygen Administration -Rethinking Interventions Alleviating Dyspnea in Patients With COPD	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of P2Y12 Receptor Inhibitors on Central and Peripheral Chemoreceptors' Sensitivity

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms